ADMINISTRATION¹

Dosing Frequency:
Every 2 Weeks (Q2W)

The ONLY FULLY HUMAN IgG2 anti-EGFR monoclonal antibody for mCRC with Q2W dosing*

* Comparative clinical significance unknown.

Infusion treatment¹

First Infusion Time:
60 minutes at doses ≤1000 mg

Subsequent Infusion Times, if the first infusion is tolerated: 30–60 minutes at doses ≤1000 mg.

The infusion time for doses >1000 mg is approximately 90 minutes

• Vectibix should be inspected visually prior to administration.
• The solution may contain a small amount of visible, translucent-to-white amorphous, proteinaceous panitumumab particulates (which will be removed by in-line filtration).
• Do not administer Vectibix if its appearance is not as described above.
• Do not mix or administer Vectibix infusion with other medicinal products.
• Do not add other medications to solutions containing Vectibix.
• Flush line before and after Vectibix administration with 0.9% sodium chloride injection USP to avoid mixing with other drug products or
  IV solutions.
• Do not administer Vectibix as an IV push or bolus.
• Vectibix must be administered using an IV infusion pump.
• Administer using a low protein binding 0.2 μm or 0.22 μm in-line filter.

Dose modifications

Infusion reactions:¹

• Reduce infusion rate by 50% in patients experiencing a mild or moderate (Grade 1 or 2) infusion reaction for the duration of that infusion.

• Stop infusion if a severe or life-threatening infusion reaction occurs. Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix.

Please consult the Product Monograph for complete dosing and administration instructions.

Q2W, every 2 weeks.